Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.73 |
| ▸ | PRKCH | P24723 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373598 | 0.84 | SYK (1.00) | SYK | |
| SCHEMBL13388645 | 0.84 | SYK (1.00) | SYKPRKCHPRKCE | |
| SCHEMBL589047 | 0.82 | SYK (1.00) | SYK | |
| SCHEMBL373604 | 0.81 | SYK (0.74) | SYKPRKCHPRKCE | |
| SCHEMBL590118 | 0.79 | SYK (1.00) | SYKPRKCHPRKCE | |
| SCHEMBL373903 | 0.77 | SYK (0.90) | SYK | |
| SCHEMBL373599 | 0.76 | SYK (0.88) | SYK | |
| SCHEMBL11365024 | 0.74 | SYK (1.00) | SYK | |
| SCHEMBL13406834 | 0.73 | SYK (1.00) | SYK | |
| SCHEMBL3287166 | 0.73 | SYK (0.70) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | claimed |
| EP-0830314-B1 | POROUS INORGANIC OXIDE MATERIALS PREPARED BY NON-IONIC SURFACTANT TEMPLATING ROUTE | UNIV MICHIGAN STATE (US) | 2002-12-18 | — | — | EP | claimed |
| US-6465387-B1 | METHOD FOR PREPARING SYNTHETIC, SEMI-CRYSTALLINE, POROUS INORGANIC OXIDE COMPOSITION CONTAINING A REACTIVE ORGANIC SILANE MOIETY WHICH IS ON THE SURFACE OR PORE WALLS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2002-10-15 | — | — | US | claimed |
| US-5800799-A | Porous inorganic oxide materials prepared by non-ionic surfactant and fluoride ion | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1998-09-01 | — | — | US | claimed |
| EP-0830314-A4 | POROUS INORGANIC OXIDE MATERIALS PREPARED BY NON-IONIC SURFACTANT TEMPLATING ROUTE | UNIV MICHIGAN STATE (US) | 1998-08-26 | — | — | EP | claimed |
| US-5795559-A | POROUS STABLE MATERIAL | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1998-08-18 | — | — | US | claimed |
| EP-0830314-A1 | POROUS INORGANIC OXIDE MATERIALS PREPARED BY NON-IONIC SURFACTANT TEMPLATING ROUTE | MICHIGAN STATE UNIVERSITY (US) | 1998-03-25 | — | — | EP | claimed |
| US-5622684-A | Porous inorganic oxide materials prepared by non-ionic surfactant templating route | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1997-04-22 | — | — | US | claimed |
| WO-1996039357-A1 | POROUS INORGANIC OXIDE MATERIALS PREPARED BY NON-IONIC SURFACTANT TEMPLATING ROUTE | MICHIGAN STATE UNIVERSITY (US) | 1996-12-12 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2008041197-A2 | RINSE-CLEANING LAUNDRY WASHING MACHINE METHOD | THE PROCTER & GAMBLE COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885PRKCH 576/4885PRKCE 745/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | SYK 466/4885PRKCH 2402/4885PRKCE 2651/4885 |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | SYK 4506/4885PRKCH 2223/4885PRKCE 1949/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885PRKCH 576/4885PRKCE 745/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | SYK 1864/4885PRKCH 266/4885PRKCE 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.